EAST HANOVER, NJ - An East Hanover resident is one of over 175 patients prescribed the anti-psychotic medication, Abilify, that are filing law suits against Bristol-Myers Squibb. The suit claims Squibb intentionally concealed the risk of developing addictive behaviors while taking Abilify.
The resident is claiming loses of over $10,000 in gambling and shopping. The resident also claims the addictive risky behaviors disappeared shortly after discontinuing Abilify. The drug contains aripiprazole, a psychotropic medication that balances dopamine and serotonin levels in the brain.
Common side effects listed include: dizziness, drowsiness, weakness, lightheadedness, nausea, vomiting, stomach upset, tiredness, excess saliva or drooling, trouble swallowing or choking, blurred vision, headache, anxiety, weight gain, drowsiness, sleep problems (insomnia), and constipation.Suicidal thoughts are may occur in some patients, especially children, teens, and young adults.
According to ClassAction.com “Until recently Abilify’s prescribing information did not mention gambling as a possible side effect despite the fact that scientific literature has linked the drug to compulsive gambling since at least 2010.”
The FDA ordered new Abilify warnings for compulsive gambling, shopping, eating and sexual activity in 2016. The law suits filed against Bristol-Myers Squibb claim financial and personal losses, neuropsychiatiric injury, physical injury, and emotional distress.
Months after the labeling dispute and pending suits, Bristol–Myers Squibb paid a 20 million dollar settlement with 43 states for the “unapproved off label” uses of Abilify and discrepant marketing practices.
The resident's law suit was filed on April 19, 2017 in The Superior Court of New Jersey, Bergen County.